FBR: Marta Cascante

03mar12:3013:30FBR: Marta Cascante

Event Details

Speaker: Marta Cascante
Institution: Dept of Biochemistry and Molecular Biomedicine-Institute of Biomedicine (IBUB) University of Barcelona , Spain
Place: Jerónimo Forteza CIPF conference room


Metabolic phenotyping from cells to tumor biopsies: towards the design of personalized therapies

Colorectal cancer (CRC) is the second leading cancer in mortality, with the vast majority of its deaths attributable to distant metastasis. Even though genetic alterations drive cancer initiation, few genetic changes are identified during the metastatic process and epigenetic or metabolic changes have emerged as hallmarks of metastasis. Current standard-of-care for metastatic colorectal cancer (mCRC) patients includes chemotherapy such as FOLFOX and anti-angiogenic or anti-EGFR in microsatellite stable (MSS). Immunotherapy only has been successful for microsatellite instable (MSI) tumors. The efficacy of chemotherapy in CRC is limited by the emergence of chemoresistance, which remarks the need of new tools for patient selection for specific therapies and for the design of new combined therapies to overcome chemoresistance.  Since metabolic reprogramming is known to be an important hallmark of cancer, tumor metabolic metabolism is considered a sensitive target in the design of combined therapies.

Here I will present our recent results characterizing metabolic adaptations of mCRC and on tools towards a metabolic classification of tumours that contribute to the identification of patient subsets more suitable for optimally tailored combined therapies.

First, I will show the workflow that we developed to integrate multiple layers of -omics data and characterize putative drug targets to impair metabolic adaptations that sustain CRC metastatic potential. Using this workflow, we built genome-scale metabolic flux models (GSMMs)Marta that allowed us to predicted and validated cystine uptake and folate metabolism as potential targets against mCRC.

Second, I will present our work in progress towards the identification of  immunometabolic distinctive phenotypes conserved across diverse tumour types and the potential that offers the metabolic stratification of tumours in the design of patient-tailored combined therapies.

Finally, I will discuss the possibilities that offer GSMMs to complement integrated physiology towards the identification of metabolic key players in metabolic diseases and to inform the design of new combined therapies.




(Friday) 12:30 - 13:30(GMT+01:00)


Centro de Investigación Príncipe Felipe

Eduardo Primo Yúfera, 3 Valencia Spain